|
3. Prévention
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
|
|
|
|
FDA Proposes New Steps to Advance Clinical Testing to Deliver New Cures [FDA]
|
|
|
|
|
|
These
developments are extremely promising. To fully realize these benefits,
it’s critical that we continue to advance a modern framework for the
development of advanced diagnostics — one that helps harness the full
potential of new diagnostics to drive better treatment decisions with
both current and future therapies, while also ensuring that such
diagnostic tests are safe and effective.
|
|
|
|
|
|
|
4.10 Dép., diag. & prono. - Poumon
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
5. Traitements
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
AbbVie's Rova-T hits yet another setback [BiopharmaDive]
|
|
|
|
|
|
Called
TAHOE, the trial compared Rova-T to the chemotherapy topotecan in
second-line advanced small cell lung cancer (SCLC). AbbVie said the
decision to halt TAHOE does not affect other Rova-T studies. However,
opportunities for the antibody-drug conjugate to prove effective are
narrowing.
|
|
|
|
|
|
|
Worse Than Useless [In the Pipeline]
|
|
|
|
|
|
If
you’re an advocate for getting the FDA out of the way by whatever way
you want to call it, because you’re convinced that it’s some sort of big
slow roadblock to live-saving drugs reaching needy patients, I have
something to say to you: Rova-T. It was new, it was promising, it was
exciting, it was first-in-class, its toxicity was manageable, its early
results were compelling, and a big drug company thought it was worth six
billion dollars in cash up front. You would have given it to all those
needy patients right then, back in 2016. Wouldn’t you? And killed them
faster.
|
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T, thérapies cellulaires
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
|
|
5.12.6 Immunothérapies - AMM
|
|
|
|
Roche's lung cancer combo treatment wins FDA approval [Reuters]
|
|
|
|
|
|
The
long-awaited FDA decision is a shot in the arm to Roche’s aspirations
of boosting Tecentriq sales in earlier lines of lung cancer treatment,
but first-mover advantage of Merck’s Keytruda has dented the medicine’s
prospects in one of cancer treatment’s most-lucrative segments.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
FDA Approves Three New Treatments for AML [Cancer Research Catalyst]
|
|
|
|
|
|
Glasdegib is a molecularly targeted therapeutic directed against a protein called Smoothened. Venetoclax is a molecularly targeted therapeutic directed against the protein BCL-2. Gilteritinib
is the third molecularly targeted therapeutic approved recently by the
FDA for the treatment of AML. It targets the protein FLT3 and it is
intended for use in the treatment of adults of any age whose leukemia
tests positive for a mutation in the FLT3 gene, and that has relapsed
after initial treatment or did not respond to initial treatment.
|
|
|
|
|
|
|
5.7.1 SABCS-communiqués
|
|
|
|
|
|
|
5.7.2 SABCS-divers
|
|
|
|
|
5.7.3 SABCS-AACR
|
|
|
|
|
|
|
|
5.7.4 SABCS-essais
|
|
|
|
6.12 Ethique
|
|
|
|
6.5 Médecines alternatives/complémentaires
|
|
|
|
6.6 Publications
|
|
|
ORCID Open Letter - Funders [ORCID]
|
|
|
|
|
|
We,
the following funding bodies, commit to implementing ORCID iDs in
accordance with their best practice guidelines for funders. We encourage
other funders to join us in this initiative.
|
|
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
6.7.1 IA/bioinformatique
|
|
|